Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Margin-accentuation IRE in Pancreatic Cancer

NCT02952859 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT02952859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Margin-accentuation IRE in Pancreatic Cancer
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Overall status
Terminated
Start date
January 31, 2017
Completion date
February 25, 2020
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer